Wealthcare Advisory Partners’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.4M | Buy |
10,304
+6
| +0.1% | +$6.13K | 0.23% | 89 |
|
|
2026
Q1 | $9.47M | Sell |
10,298
-540
| -5% | -$547K | 0.18% | 115 |
|
|
2025
Q4 | $11.6M | Buy |
10,838
+322
| +3% | +$308K | 0.23% | 95 |
|
|
2025
Q3 | $8.02M | Buy |
10,516
+126
| +1% | +$93.8K | 0.17% | 118 |
|
|
2025
Q2 | $8.1M | Sell |
10,390
-183
| -2% | -$142K | 0.18% | 110 |
|
|
2025
Q1 | $8.73M | Buy |
10,573
+829
| +9% | +$690K | 0.23% | 85 |
|
|
2024
Q4 | $7.52M | Sell |
9,744
-508
| -5% | -$421K | 0.21% | 93 |
|
|
2024
Q3 | $9.08M | Buy |
10,252
+844
| +9% | +$759K | 0.26% | 77 |
|
|
2024
Q2 | $8.52M | Buy |
9,408
+574
| +6% | +$459K | 0.27% | 68 |
|
|
2024
Q1 | $6.87M | Buy |
8,834
+2,400
| +37% | +$1.71M | 0.23% | 80 |
|
|
2023
Q4 | $3.75M | Buy |
6,434
+659
| +11% | +$385K | 0.15% | 114 |
|
|
2023
Q3 | $3.1M | Buy |
5,775
+154
| +3% | +$79.4K | 0.14% | 115 |
|
|
2023
Q2 | $2.64M | Buy |
5,621
+10
| +0.2% | +$4.19K | 0.12% | 147 |
|
|
2023
Q1 | $1.93M | Buy |
5,611
+340
| +6% | +$115K | 0.08% | 182 |
|
|
2022
Q4 | $1.93M | Buy |
5,271
+1,875
| +55% | +$665K | 0.09% | 166 |
|
|
2022
Q3 | $1.1M | Buy |
3,396
+263
| +8% | +$83.3K | 0.06% | 222 |
|
|
2022
Q2 | $1.02M | Buy |
3,133
+59
| +2% | +$17.7K | 0.06% | 203 |
|
|
2022
Q1 | $880K | Buy |
3,074
+249
| +9% | +$64.1K | 0.05% | 215 |
|
|
2021
Q4 | $780K | Buy |
2,825
+291
| +11% | +$73.8K | 0.05% | 234 |
|
|
2021
Q3 | $586K | Sell |
2,534
-258
| -9% | -$63.7K | 0.04% | 290 |
|
|
2021
Q2 | $641K | Sell |
2,792
-429
| -13% | -$86.2K | 0.04% | 265 |
|
|
2021
Q1 | $602K | Buy |
3,221
+1,270
| +65% | +$248K | 0.04% | 253 |
|
|
2020
Q4 | $329K | Buy |
+1,951
| New | +$291K | 0.03% | 307 |
|
|
2020
Q2 | – | Sell |
-923
| Closed | -$128K | – | 915 |
|
|
2020
Q1 | $128K | Buy |
923
+224
| +32% | +$30.8K | 0.02% | 331 |
|
|
2019
Q4 | $92K | Buy |
699
+2
| +0.3% | +$232 | 0.01% | 421 |
|
|
2019
Q3 | $78K | Sell |
697
-280
| -29% | -$31.2K | 0.01% | 442 |
|
|
2019
Q2 | $108K | Buy |
977
+3
| +0.3% | +$353 | 0.02% | 362 |
|
|
2019
Q1 | $126K | Buy |
974
+4
| +0.4% | +$486 | 0.02% | 300 |
|
|
2018
Q4 | $112K | Sell |
970
-77
| -7% | -$8.6K | 0.02% | 288 |
|
|
2018
Q3 | $112K | Sell |
1,047
-652
| -38% | -$65.2K | 0.02% | 317 |
|
|
2018
Q2 | $145K | Buy |
1,699
+512
| +43% | +$42.1K | 0.03% | 263 |
|
|
2018
Q1 | $92K | Sell |
1,187
-436
| -27% | -$35.1K | 0.02% | 293 |
|
|
2017
Q4 | $137K | Sell |
1,623
-33
| -2% | -$2.81K | 0.04% | 221 |
|
|
2017
Q3 | $142K | Buy |
+1,656
| New | +$136K | 0.04% | 176 |
|
Other funds holding LLY
Wealthcare Advisory Partners's LLY Position: Q2 2026 in Review
Wealthcare Advisory Partners increased its Eli Lilly (LLY) stake by 0.06% in Q2 2026, buying an estimated $6.13K and bringing the position to 10,304 shares worth $12.4M. The position accounts for 0.23% of the portfolio, ranked #89.
Wealthcare Advisory Partners first reported a position in LLY in Q3 2017 and has held it in 34 quarters since. 4,614 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Wealthcare Advisory Partners held 10,304 shares of Eli Lilly worth $12.4M as of Q2 2026.
- Wealthcare Advisory Partners bought 6 Eli Lilly shares in Q2 2026, an estimated $6.13K.
- Eli Lilly made up 0.23% of Wealthcare Advisory Partners's portfolio in Q2 2026, its #89 holding.
- Wealthcare Advisory Partners first reported a position in Eli Lilly in Q3 2017 and has held it in 34 quarters since.
- 4,614 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Wealthcare Advisory Partners's 13F filing for Q2 2026, filed 9 Jul 2026.